Hey there! Before reading the article which is about Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces April 2021 as the Best Revenue Month in Company History, you should read about mjna stock price. It shares basic information about this article and also adds more value to it. Do let us know how you feel about it in the comment section below. Happy Reading! Really glad that you are here.

It’s official: HempMeds® Brasil has set a new company record for monthly revenue in a single country! The subsidiary of Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its sales for April were greater than ever before. (HempMeds® Brasil is in the business of importing and distributing hemp-based cannabidiol [CBD] products for the treatment of health conditions including epilepsy, Crohn’s Disease, cancer, multiple sclerosis, and chronic pain.)

Medical Marijuana, Inc. (OTC: MJNA) subsidiary HempMeds® Brasil (“HMB”) announced today that the company will earn a record $2,458,983 in total revenue for the month of April, exceeding the previous record set in March by more than $1,000,000. The previous record for a single month was $1,452,000. The single month record was set in March when the company began its HempMeds® CBD Oil business.

SAN DIEGO, CA, May 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the Company), the first U.S. publicly traded cannabis company to launch the world’s first cannabis-based nutraceutical products, brands and supply chains, today announced that its HempMeds® Brasil subsidiary achieved the highest revenue in the Company’s history in April 2021.

Our company, HempMeds Brasil, has experienced steady growth over the years. We strive to reach as many consumers in need as possible, and last month’s success proves that we continue to expand our reach, said Dr. Stuart Titus, CEO of Medical Marijuana, Inc.

I am incredibly proud of the success that the HempMeds Brasil team has achieved. As we celebrate the best sales month in the company’s history, we are expanding our operations in the country, updating our consumer website and strengthening our presence in Brazil to meet the needs of our growing team, said Raul Elizalde, CEO of HempMeds®.

In the coming months, to support our continued growth, we plan to partner with Brazil’s largest institute of higher learning to educate healthcare professionals on the potential benefits of cannabidiol (CBD) and to partner with respected professional and Olympic athletes, said Mateus Patelli, CEO of HempMeds® Brasil. My team has been successful in showing the people of Brazil that our products are of the highest quality and as reliable as the people who work for the company.

For more information on HempMeds® Brasil, visit www.hempmeds.com.br.

About HempMeds® Brasil
HempMeds® Brasil was the first company to receive approval from the National Health Inspectorate (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a cannabis plant. The company is now licensed to distribute its products, which help treat conditions such as epilepsy, Parkinson’s disease, chronic pain and multiple sclerosis, by prescription. For these indications, the products may be subsidized by the Brazilian government. HempMeds® Brasil is working on additional approvals for other indications. www.hempmeds.com.br

About Medical Marijuana, Inc.
We are a Firsts® company. Medical Marijuana, Inc. (MJNA) is a cannabis company that owns three separate non-psychoactive cannabinoid businesses: A global portfolio of cannabinoid-based nutraceutical brands led by Kannaway®and HempMeds®; a pioneer in the research of high quality, legal, non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and drug development company led by investment companies and pharmaceutical partners, including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. is a top CBD manufacturer named by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import licenses for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay, and is a leader in developing international markets. The company’s flagship product, Real Scientific Hemp Oil, has been used in several successful clinical trials in Mexico and Brazil to evaluate its safety and efficacy.

Medical Marijuana, Inc. is headquartered in San Diego, CA. For more information, visit OTCMarkets.comor www.medicalmarijuanainc.com. To view the corporate video of Medical Marijuana, Inc, click here.

Shareholders and consumers are also encouraged to purchase CBD oil and other products from Medical Marijuana, Inc.


This press release may contain certain forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those Sections. This document contains statements about expected future events and/or financial results that are subject to risks and uncertainties. By definition, these forward-looking statements involve risks, uncertainties and other factors that could cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ materially from those expressed herein.


These claims have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


Medical Marijuana, Inc. does not sell or distribute products in violation of the U.S. Controlled Substances Act.


Public relations contact person :
Catherine Brown
Account Executive
CMW Media
P. 858-264-6600
[email protected]

Investor Relations Contact :
P. (858) 283-4016
[email protected]


Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces April 2021 as the Best Revenue Month in Company History

Privacy settings,How Search works,mjna stock price

You May Also Like

What’s New With Cannabis Stocks for the Week Ending 05/21/21

The cannabis stocks that led the way last week are poised to…

Ayr Strategies Q1 Revenue Increases 74% to $58.4 Million

Ayr Strategies Q1 Revenue Increases 74% to $58.4 Million Ayr Strategies Inc.…

Red White & Bloom Raises $44.5 Million in Debt and Subsidiary…

Red White & Bloom, a wholly-owned subsidiary of High Yields Cannabis Company,…

KushCo Holdings Sees Q3 Revenue at $27.5-28 Million

KushCo Holdings, a publicly traded company that buys and sells many different…